What is Sarepta Therapeutics, Inc.'s market cap?

Sarepta Therapeutics, Inc. (SRPT) has a market capitalization of $1.7B and trades on NASDAQ.

What is Sarepta Therapeutics, Inc.'s revenue and profitability?

Sarepta Therapeutics, Inc. generated $2.2B in trailing twelve-month revenue with a net loss of $579.3M, representing a net margin of 4.6%, with free cash flow of -$977.3M. These figures are based on the Q1 2026 filing.

Who are Sarepta Therapeutics, Inc.'s competitors?

Sarepta Therapeutics, Inc.'s key competitors include Pfizer Inc., Solid Biosciences Inc., Regeneron Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.

Who does Sarepta Therapeutics, Inc. partner with?

Sarepta Therapeutics, Inc.'s notable partners include Arrowhead Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd, Catalent Maryland, Inc., and others.

What subsidiaries does Sarepta Therapeutics, Inc. have?

Sarepta Therapeutics, Inc.'s subsidiaries include Sarepta Therapeutics Investments, Inc., Myonexus Therapeutics Inc..

Where is Sarepta Therapeutics, Inc. headquartered?

Sarepta Therapeutics, Inc. is headquartered in United States of America and employs approximately 1,314 people. It has been publicly traded since 1997.

Sarepta Therapeutics, Inc.

SRPT

Sarepta Therapeutics is a commercial-stage biopharmaceutical company specializing in precision genetic medicines for rare diseases.

Market cap

$1.68B+1.9%

Revenue$2.2B+9.9%

Net income-$579.3M-346%

Free cash flow-$977.3M-92.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$730.8MBeat by $256.6M EPS$3.16Beat by $2.18

Read the full report

Next report

Aug 5, 2026 (In 6 days)

Revenue estimate$382.0M

EPS estimate$0.49

Financials

Q1 2026

Income statement

See full

Revenue$730.8M-1.9%

Net income$331.0M+174%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation & ratios

Valuation

See full

Market cap$1.68B+1.9%

Enterprise value$1.41B+32.4%

P/S0.8×—

Returns & leverage

See full

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Segments

By segment

See full

All Other Segments$730.8M-1.9%

Competitors

By market cap

Pfizer$140.61B+1.7%

Regeneron Pharmaceuticals$69.9B+16.0%

Sarepta Therapeutics, Inc.$1.7B+23.2%

Solid Biosciences Inc.$776.8M+42.7%

Design Therapeutics, Inc.$742.0M+224%

Tenaya Therapeutics, Inc.$167.0M+31.6%

Korro Bio, Inc.$154.6M+5.5%

enGene Therapeutics Inc. $117.9M-36.6%

By revenue growth

Sarepta Therapeutics, Inc.+9.9%

Regeneron Pharmaceuticals+5.9%

Pfizer+1.4%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Pfizer15.65%+6.3pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Solid Biosciences Inc.-1,062.28%—

Design Therapeutics, Inc.-3,663.72%—

Profile

Sarepta Therapeutics is a commercial-stage biopharmaceutical company specializing in precision genetic medicines for rare diseases. The company leverages proprietary RNA-targeted, gene therapy, and siRNA technologies to treat neuromuscular and skeletal disorders. Its core value proposition lies in developing first-in-class treatments for Duchenne muscular dystrophy and other debilitating genetic conditions with high unmet medical needs.

Competitive position

A leading developer of genetic medicines for Duchenne muscular dystrophy with multiple first-to-market approved products and a deep pipeline in gene therapy.

GeographiesUnited States, European Union, Israel, Middle East

Customer segmentsRare disease patients, Specialty healthcare providers, International health authorities

Business modelProduct-based, Research and Development, Licensing and Royalties

SuppliersContract Manufacturing Organizations (CMOs), Plasmid suppliers, Academic research institutions, Specialized raw material providers

CustomersSpecialty pharmacies, Third-party logistics providers, Hospitals, Government health programs, Private health insurers

CountryUnited States of America

Listed1997

Employees1.3K

CEODouglas S. Ingram

SectorHealthcare

IndustryBiotechnology

Websitesarepta.com

FilingsSEC EDGAR

Ask your AI about Sarepta Therapeutics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s market cap?: Sarepta Therapeutics, Inc. (SRPT) has a market capitalization of $1.7B and trades on NASDAQ.
What is Sarepta Therapeutics, Inc.'s revenue and profitability?: Sarepta Therapeutics, Inc. generated $2.2B in trailing twelve-month revenue with a net loss of $579.3M, representing a net margin of 4.6%, with free cash flow of -$977.3M. These figures are based on the Q1 2026 filing.
Who are Sarepta Therapeutics, Inc.'s competitors?: Sarepta Therapeutics, Inc.'s key competitors include Pfizer Inc., Solid Biosciences Inc., Regeneron Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
Who does Sarepta Therapeutics, Inc. partner with?: Sarepta Therapeutics, Inc.'s notable partners include Arrowhead Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd, Catalent Maryland, Inc., and others.
What subsidiaries does Sarepta Therapeutics, Inc. have?: Sarepta Therapeutics, Inc.'s subsidiaries include Sarepta Therapeutics Investments, Inc., Myonexus Therapeutics Inc..
Where is Sarepta Therapeutics, Inc. headquartered?: Sarepta Therapeutics, Inc. is headquartered in United States of America and employs approximately 1,314 people. It has been publicly traded since 1997.